JAMA Dermatology

<jats:sec><jats:title>Importance</jats:title><jats:p>Office-based phototherapy is cost-effective for psoriasis but difficult to access. Home-based phototherapy is patient preferred but has limited clinical data, particularly in patients with darker skin.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To compare the effectiveness of home- vs office-based narrowband UV-B phototherapy for psoriasis.</jats:p></jats:sec><jats:sec><jats:title>Design, Setting, and Participants</jats:title><jats:p>The Light Treatment Effectiveness study was an investigator-initiated, pragmatic, open-label, parallel-group, multicenter, noninferiority randomized clinical trial embedded in routine care at 42 academic and private clinical dermatology practices in the US. Enrollment occurred from March 1, 2019, to December 4, 2023, with follow-up through June 2024. Participants were 12 years and older with plaque or guttate psoriasis who were candidates for home- and office-based phototherapy.</jats:p></jats:sec><jats:sec><jats:title>Interventions</jats:title><jats:p>Participants were randomized to receive a home narrowband UV-B machine with guided mode dosimetry or routine care with office-based narrowband UV-B for 12 weeks, followed by an additional 12-week observation period.</jats:p></jats:sec><jats:sec><jats:title>Main Outcomes and Measures</jats:title><jats:p>The coprimary effectiveness outcomes were Physician Global Assessment (PGA) dichotomized as clear/almost clear skin (score of ≤1) at the end of the intervention period and Dermatology Life Quality Index (DLQI) score of 5 or lower (no to small effect on quality of life) at week 12.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of 783 patients enrolled (mean [SD] age, 48.0 [15.5] years; 376 [48.0%] male), 393 received home-based phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SPT) I/II,  350 (44.7%) having SPT III/IV, and 83 (10.6%) having SPT V/VI. A total of 93 patients (11.9%) were receiving systemic treatment. At baseline, mean (SD) PGA was 2.7 (0.8) and DLQI was 12.2 (7.2). At week 12, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (52.4%) and 131 (33.6%) achieved DLQI of 5 or lower, respectively. Home-based phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population and across all SPTs. Home-based phototherapy, compared to office-based phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients [15.9%]; <jats:italic>P</jats:italic> &amp;amp;lt; .001), lower burden of indirect costs to patients, and more episodes of persistent erythema (466 of 7957 treatments [5.9%] vs 46 of 3934 treatments [1.2%]; <jats:italic>P</jats:italic> &amp;amp;lt; .001). Both treatments were well tolerated with no discontinuations due to adverse events.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Relevance</jats:title><jats:p>In this randomized clinical trial, home-based phototherapy was as effective as office-based phototherapy for plaque or guttate psoriasis in everyday clinical practice and had less burden to patients.</jats:p></jats:sec><jats:sec><jats:title>Trial Registration</jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT03726489">NCT03726489</jats:ext-link></jats:p></jats:sec>

Psoriasis and comorbid diseases: epidemiology.

J Am Acad Dermatol

Risk of myocardial infarction in patients with psoriasis.

JAMA

Psoriasis and the risk of diabetes: a prospective population-based cohort study.

Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom.

J Invest Dermatol

Shared genetic risk factors and causal association between psoriasis and coronary artery disease.

Nat Commun

Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.

Br J Dermatol

Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study.

Psoriasis and mortality in the United States: data from the National Health and Nutrition Examination Survey.

Psoriasis.

Lancet

Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French Health Insurance Database.

JAMA Dermatol

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.

Sci Rep

Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR.

Factors influencing patient preferences for phototherapy: a survey study.

Cutis

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.

Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study.

J Eur Acad Dermatol Venereol

Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: a retrospective cohort study.

Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.

Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial.

Circ Cardiovasc Imaging

Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: a randomized controlled study.

Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis.

Int J Dermatol

The pipeline and market for psoriasis drugs.

Nat Rev Drug Discov

Role of phototherapy in the era of biologics.

The PRECIS-2 tool: designing trials that are fit for purpose.

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.

Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?

Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis.

Biological treatments for moderate-to-severe psoriasis: indirect comparison.

J Clin Pharm Ther

Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences.

Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study).

Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review.

J Dermatolog Treat

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev

Effect of availability of at-home phototherapy on the use of systemic medications for psoriasis.

Photodermatol Photoimmunol Photomed

Home narrowband UV-B treatment for psoriasis: a cohort study.

Systematic review of UV-based therapy for psoriasis.

Am J Clin Dermatol

Prescribing patterns associated with biologic therapies for psoriasis from a United States medical records database.

J Drugs Dermatol

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.

The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy.

The duration of clinical remission of photochemotherapy and narrow-band UV-B phototherapy in the treatment of psoriasis: a retrospective study.

Int J Immunopathol Pharmacol

The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a prospective randomized clinical trial.

Duration of remission period of narrowband ultraviolet B therapy on psoriasis vulgaris.

J Dermatol

Office-based phototherapy is cost-effective for psoriasis but difficult to access. Home-based phototherapy is patient preferred but has limited clinical data, particularly in patients with darker skin.
To compare the effectiveness of home- vs office-based narrowband UV-B phototherapy for psoriasis.
The Light Treatment Effectiveness study was an investigator-initiated, pragmatic, open-label, parallel-group, multicenter, noninferiority randomized clinical trial embedded in routine care at 42 academic and private clinical dermatology practices in the US. Enrollment occurred from March 1, 2019, to December 4, 2023, with follow-up through June 2024. Participants were 12 years and older with plaque or guttate psoriasis who were candidates for home- and office-based phototherapy.
Participants were randomized to receive a home narrowband UV-B machine with guided mode dosimetry or routine care with office-based narrowband UV-B for 12 weeks, followed by an additional 12-week observation period.
The coprimary effectiveness outcomes were Physician Global Assessment (PGA) dichotomized as clear/almost clear skin (score of ≤1) at the end of the intervention period and Dermatology Life Quality Index (DLQI) score of 5 or lower (no to small effect on quality of life) at week 12.
Of 783 patients enrolled (mean [SD] age, 48.0 [15.5] years; 376 [48.0%] female), 393 received home-based phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SPT) I/II, 350 (44.7%) having SPT III/IV, and 83 (10.6%) having SPT V/VI. A total of 93 patients (11.9%) were receiving systemic treatment. At baseline, mean (SD) PGA was 2.7 (0.8) and DLQI was 12.2 (7.2). At week 12, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (52.4%) and 131 (33.6%) achieved DLQI of 5 or lower, respectively. Home-based phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population and across all SPTs. Home-based phototherapy, compared to office-based phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients [15.9%]; P < .001), lower burden of indirect costs to patients, and more episodes of persistent erythema (466 of 7957 treatments [5.9%] vs 46 of 3934 treatments [1.2%]; P < .001). Both treatments were well tolerated with no discontinuations due to adverse events.
In this randomized clinical trial, home-based phototherapy was as effective as office-based phototherapy for plaque or guttate psoriasis in everyday clinical practice and had less burden to patients.
ClinicalTrials.gov Identifier: NCT03726489.

Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial.

Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis

Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions